百奧賽圖(02315.HK):已就RenMice系列小鼠達成50項合作
百奧賽圖(02315.HK)公布,公司自主研發、具有獨立知識產權的系列全人抗體及TCR小鼠,將採用「RenMice」為統稱。
截至今年6月底,百奧賽圖已與20家生物製藥及生物技術公司,達成RenMice小鼠授權用於42個靶點抗體開發專案。「千鼠萬抗」計劃啟動後,公司就RenMice小鼠產生的全人抗體分子已達成50項藥物合作開發、授權及轉讓協議,預期隨著計劃達到階段性里程碑進展,完成近千個靶點抗體分子貨架構建,對外分子合作開發、授權、轉讓的節奏與專案數量預計會大大提高。
公司表示,未來將繼續研發不同遺傳背景的RenMice系列小鼠,滿足不同靶點藥物的開發需求,同時針對MHC、NK cell等基因簇的全人小鼠的開發正在進行中,預計新的技術平台成功研發,將會進一步增強公司在藥物開發中的技術實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.